Core Viewpoint - AnaptysBio is undergoing a significant transformation, planning to separate into two distinct businesses by the second quarter of 2025, referred to as Biopharma Co and Royalty Management Co [1] Group 1: Business Structure - The separation will create two entities: Biopharma Co, which will focus on clinical assets, and Royalty Management Co [1] - Biopharma Co will be anchored by three clinical assets, with ANB033 being a key driver for the operating business [2] Group 2: Clinical Development - ANB033 is currently enrolling patients in a Phase Ib trial for celiac disease and initiating a second Phase Ib trial for eosinophilic esophagitis (EoE) [2] - Rosnilimab, another asset, has shown positive Phase IIb results in an arthritis trial, with plans to explore Phase III development and secure necessary capital [2] - An end of Phase II meeting with the FDA is scheduled for the next quarter to discuss the progression of Rosnilimab [2]

Group 1 - British insurer Prudential has appointed Douglas Flint as its new chair, succeeding Shriti Vadera [1] - Shriti Vadera will step down in May after serving five years in the role [1]

Summary of AnaptysBio Conference Call Company Overview - **Company**: AnaptysBio - **Event**: 44th Annual JPMorgan Healthcare Conference - **CEO**: Dan Faga Key Points Company Separation - AnaptysBio plans to separate into two distinct businesses: BiopharmaCo and Royalty Management Co by Q2 2025 [1][2][34] - The separation aims to align different business strategies and investment philosophies, enhancing shareholder value [44][46] BiopharmaCo Developments - **Clinical Assets**: BiopharmaCo will focus on three clinical assets, primarily driven by AMB033, which is currently in phase 1b trials for Celiac disease and Eosinophilic Esophagitis (EoE) [2][12] - **AMB033**: A CD122 antagonist targeting IL-15 and IL-2 signaling, showing potential in treating Celiac disease and EoE [12][26] - **Market Opportunity**: Celiac disease has over 1 million diagnosed patients in the U.S., with a $5 billion market targeting those non-responsive to a gluten-free diet [16][17] Royalty Management Co Developments - The Royalty Management Co will manage royalties from Jemperli and Imsidolimab, with significant revenue potential from these assets [3][4] - **Jemperli**: Generated over $300 million in revenue in Q3 2025, with a tiered royalty structure starting at 8% and potentially reaching 25% at peak sales [4][5] - **Imsidolimab**: Expected approval in the U.S. later this year, with a 10% flat royalty from sales [6][7] Clinical Trials and Data - **Celiac Disease Trials**: The phase 1b trial will enroll 60 patients, focusing on preventing villus atrophy and healing damaged villi [22][50] - **EoE Trials**: A trial for EoE is set to initiate later this quarter, targeting a growing market currently dominated by Dupixent [25][54] - **Rosnilimab**: A phase 2b trial in rheumatoid arthritis showed positive results, with plans for a phase 3 program pending strategic partnerships or financing [28][29] Financial Position - AnaptysBio has $310 million in cash, sufficient to support ongoing trials and operations for the next couple of years [3][34] - The company anticipates paying down $250 million of its $600 million non-recourse debt by the end of 2025 [5][41] Market Competition and Strategy - Jemperli competes with Keytruda, with GSK focusing on differentiated data in women's cancers [11] - AnaptysBio's strategy includes targeting both IL-15 and IL-2 pathways, which may provide advantages over existing therapies [12][54] Litigation with GSK - Ongoing litigation with GSK regarding Jemperli is not expected to impede the separation of the biopharma business [39][40] - AnaptysBio claims GSK has breached contract terms, with a trial date set for July 2025 [41][43] Future Outlook - AnaptysBio is optimistic about the potential of its clinical assets and the upcoming separation, which is expected to create value for shareholders [46][49] - The company is exploring various financing options to support the advancement of its clinical programs [48][49] Additional Insights - The separation is seen as a strategic move to unlock value by allowing each entity to pursue tailored growth strategies [44][46] - The focus on both Celiac disease and EoE highlights AnaptysBio's commitment to addressing unmet medical needs in immunology [12][54]

Core Insights - AnaptysBio reported a significant insider sale by Director J. Anthony Ware, who sold 3,900 shares for $193,342.50, representing 28.82% of his direct holdings, during a period of strong share price gains [1][2][10] Company Overview - AnaptysBio is a clinical-stage biotechnology company focused on developing antibody therapies for inflammatory and immune-mediated diseases [8] - The company has a market capitalization of $1.39 billion and reported revenue of $169.47 million for the trailing twelve months (TTM) [4] - The stock price increased by 264.63% over the past year, significantly outperforming the S&P 500's 17% gain [4][11] Transaction Details - The transaction involved a sale of 3,900 shares at a price of $49.58, with a post-transaction value of $481,885.20 based on the market close of $50.04 [2][4] - Post-transaction, Ware retains 9,630 shares and has options to purchase an additional 126,085 shares, along with 6,030 restricted stock units, indicating continued economic alignment with the company [10] Context of the Sale - This sale marks Ware's first open-market transaction at AnaptysBio, contrasting with previous administrative filings, suggesting a strategic decision rather than a shift in outlook [6][10] - The timing of the sale coincided with a high stock price following a substantial one-year return, indicating that the sale was likely a portfolio management decision [6][11] Company Performance - AnaptysBio reported $256.7 million in cash and investments at the end of the third quarter, with collaboration revenue increasing to $76.3 million from $30 million a year earlier [11] - The company's strong balance sheet and revenue visibility support the underlying investment thesis despite insider selling [11]

This clinical-stage biotech specializing in antibody therapeutics reported a notable insider sale amid ongoing development and partnerships.Paul F. Lizzul, the chief medical officer of AnaptysBio (ANAB +1.99%), reported the direct sale of 3,650 shares of the company for a total consideration of approximately $163,191.50 on Thursday, as disclosed in a recent SEC Form 4 filing.Transaction summaryMetricValueShares sold (direct)3,650Transaction value$163,191.50Post-transaction shares (direct)42,088Post-transact ...

Financial Performance - As of year-end 2025, the company has approximately $310 million in cash, including a one-time $75 million milestone from GSK due to Jemperli achieving $1 billion in worldwide net sales in November 2025[6]. - Jemperli generated $303 million in Q3 2025, reflecting a greater than 16% quarter-over-quarter growth rate, with an annualized run rate exceeding $1.2 billion[14]. - The company expects to receive over $390 million annually in Jemperli royalties at GSK's peak sales guidance of over $2.7 billion, anticipated to be achieved before 2031[14]. - Jemperli's revenue forecasts indicate a steep growth trajectory, with projected sales reaching over $2 billion by 2031[16]. Corporate Strategy - The company plans to separate into two independent publicly traded entities by Q2 2026 to maximize shareholder value[6]. - The anticipated paydown of financial obligations to Sagard is projected between Q2 2027 and Q1 2028, based on Jemperli's continued strong growth[14]. - The company anticipates minimal infrastructure and staff requirements post-separation, focusing on protecting and returning value from royalty assets[6]. - The company is focused on expanding its market presence and enhancing its product pipeline through ongoing clinical trials and research[116]. Clinical Trials and Drug Development - The company is initiating a Phase 1b clinical trial for ANB033 in Eosinophilic Esophagitis in Q1 2026, with top-line data from the Phase 1b trial in Celiac Disease expected in Q4 2026[8]. - Imsidolimab has received FDA BLA submission for generalized pustular psoriasis (GPP) in December 2025, with potential approval as early as mid-2026[14]. - The ongoing Phase 1b trial in Celiac Disease (CeD) anticipates top-line data in Q4 2026, with a focus on mucosal healing and prevention of mucosal damage[56]. - The ongoing Phase 1b trial for ANB033 is set to initiate in Q1 2026, focusing on its efficacy in treating eosinophilic esophagitis[66]. - The Phase 1a trial of ANB033 in healthy volunteers showed no serious adverse events (SAEs) or severe adverse events (AEs), indicating favorable safety and tolerability[36]. - The Phase 2b trial for ulcerative colitis showed a favorable safety and tolerability profile, but the lack of efficacy at Week 12 led to the decision to discontinue further development in this indication[126]. Drug Mechanism and Efficacy - ANB033 demonstrated a statistically significant survival benefit in a GvHD mouse model compared to isotype control (P<0.0001) and Belatacept (P=0.003) with a 60-day study showing body weight loss was also significantly reduced (P<0.001)[32]. - ANB033 exhibited a favorable pharmacokinetic (PK) profile with a half-life of 2 to 3 weeks and full receptor occupancy maintained for over 30 days[36]. - The drug's mechanism of action targets excessive IL-15 and IL-2 production, which are key drivers of CeD inflammation[42]. - ANB033 treatment preserved villus height and crypt depth in a CeD mouse model, indicating improved histological outcomes[46]. - ANB033 significantly reduced CD122+ NK cells by over 50% with a return towards baseline within 3 months, demonstrating its potential in CeD treatment[40]. - Rosnilimab shows a best-in-disease profile in rheumatoid arthritis (RA) with a market potential of approximately $20 billion in the U.S., the first new mechanism approved since 2012[88]. - Rosnilimab demonstrated JAK-like efficacy with comparable response rates across more stringent endpoints regardless of prior therapy type, including JAKs[100]. Market Potential and Demographics - The U.S. market for patients non-responsive to a gluten-free diet is projected to be $4-5 billion, with an initial target population of approximately 1.1 million diagnosed patients[62]. - There are about 340,000 diagnosed U.S. patients with eosinophilic esophagitis (EoE), with 170,000 being biologic-eligible and around 30,000 currently treated with Dupixent[74]. - The prevalence of EoE is increasing at a compound annual growth rate (CAGR) of over 8%, with anticipated U.S. sales exceeding $5 billion by 2030[74]. - The target population for rheumatoid arthritis (RA) in the US generated approximately $10 billion in 2021, with over $1 billion in sales from Rituxan and biosimilars in the third-line treatment despite infection risks[124]. - The prevalence of RA in the US is around 1.8 million, with approximately 1 million treated with biologics and JAK inhibitors, and about 500,000 in the second-line treatment category[124]. Safety and Tolerability - Rosnilimab's safety and tolerability were favorable compared to standard of care, with strict continuation criteria preventing patients with improvement at 3 months from continuing in the trial[88]. - Serious adverse events (SAEs) were low across treatment groups, with only one ischemic stroke reported in the 100 mg group[122]. - The company observed a 90% depletion of pathogenic T cells in the Phase 2 trial for RA, indicating expected pharmacological activity[126]. - Rosnilimab demonstrated a well-tolerated safety profile with a dropout rate of less than 2% due to adverse events (AEs) over six months, with only one dropout attributed to a moderate headache[122]. Competitive Landscape - The incidence of serious adverse events (SAEs) in commercial products with black box warnings has not hindered their sales, with RA sales reaching $4.5 billion for one product[120]. - Rosnilimab's competitive landscape shows it as a best-in-class T cell depleter, outperforming competitors in pathogenic T cell depletion[116]. - The market for RA treatments remains fragmented, with no clear treatment of choice after anti-TNF failures, presenting an opportunity for new biologics[124].

Core Viewpoint - AnaptysBio has filed a partial motion to dismiss a claim from GSK's oncology unit regarding a breach of contract related to royalties from the cancer drug Jemperli [1] Group 1 - AnaptysBio is currently involved in a legal dispute with GSK's oncology unit [1] - The dispute centers around allegations that AnaptysBio breached their contract [1] - The claim involves royalties tied to the sales of the cancer drug Jemperli [1]

Core Viewpoint - AnaptysBio is engaged in a legal dispute with Tesaro and GSK regarding a Collaboration and Exclusive License Agreement, with a trial scheduled for July 14-17, 2026, to resolve all claims [1]. Group 1: Legal Proceedings - Anaptys filed a partial motion to dismiss Tesaro's anticipatory breach of contract claim in Delaware Chancery Court [1]. - Tesaro initiated a lawsuit against Anaptys on November 20, 2025, claiming Anaptys had repudiated the Collaboration Agreement [2]. - Anaptys responded with its own complaint, asserting that Tesaro materially breached the Collaboration Agreement and that GSK tortiously interfered with it [3]. Group 2: Motion to Dismiss - Anaptys filed a Motion to Dismiss Tesaro's claim on December 30, 2025, arguing that it has not repudiated the Collaboration Agreement and is merely asserting its contract rights [4]. - The motion also invokes Delaware's anti-SLAPP law, which aims to prevent lawsuits that deter good-faith legal rights assertions [4]. - Tesaro and GSK argue that Anaptys' Motion to Dismiss should stay all discovery, which Anaptys opposes as they prepare for the upcoming trial [5]. Group 3: Collaboration Agreement Details - The Collaboration Agreement, established in March 2014, allows Anaptys to receive royalties from Jemperli sales, structured as follows: 8% for net sales below $1 billion, 12% for sales between $1 billion and $1.5 billion, 20% for sales between $1.5 billion and $2.5 billion, and 25% for sales above $2.5 billion [6][7]. - The royalty term extends until at least the expiration of composition of matter coverage, which is set to expire in 2035 in the U.S. and 2036 in the EU [7]. Group 4: Company Overview - AnaptysBio is a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases [8]. - The company's pipeline includes several candidates, such as rosnilimab for rheumatoid arthritis and ANB033 for celiac disease [8]. - Anaptys plans to separate its biopharma operations from its royalty assets by the end of 2026 to better align with investor interests [9].

Core Viewpoint - AnaptysBio is engaged in a legal dispute with Tesaro and GSK regarding a Collaboration and Exclusive License Agreement, with a trial scheduled for July 14-17, 2026 [1][5]. Group 1: Legal Proceedings - Anaptys filed a partial motion to dismiss Tesaro's anticipatory breach of contract claim in Delaware Chancery Court [1]. - Tesaro initiated a lawsuit against Anaptys on November 20, 2025, claiming Anaptys had repudiated the Collaboration Agreement [2]. - Anaptys responded with its own complaint, asserting that Tesaro materially breached the Collaboration Agreement and that GSK tortiously interfered with it [3]. Group 2: Collaboration Agreement Details - The Collaboration Agreement, established in March 2014, allows Anaptys to receive royalties from sales of Jemperli, with rates of 8% for net sales below $1 billion, 12% for sales between $1 billion and $1.5 billion, 20% for sales between $1.5 billion and $2.5 billion, and 25% for sales above $2.5 billion [6][7]. - The royalty term extends at least until the expiration of composition of matter coverage in 2035 in the U.S. and 2036 in the EU [7]. Group 3: Company Overview - AnaptysBio is a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases [8]. - The company's pipeline includes several candidates, such as rosnilimab for rheumatoid arthritis and ANB033 for celiac disease [8]. - Anaptys plans to separate its biopharma operations from its royalty assets by the end of 2026 to better align with investor interests [9].

SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan 13, 2026 at 4:30pm PT / 7:30pm ET. A live webcast of the presentation will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presen ...